R165
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 69
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.370
- WNT_BETA_CATENIN_SIGNALING+0.220
- DNA_REPAIR+0.180
- NOTCH_SIGNALING+0.130
- UNFOLDED_PROTEIN_RESPONSE+0.130
- HEME_METABOLISM+0.090
- P53_PATHWAY+0.070
- ADIPOGENESIS+0.040
- BILE_ACID_METABOLISM+0.040
- FATTY_ACID_METABOLISM+0.000
Top 10 suppressed
- ANGIOGENESIS-0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- COAGULATION-0.370
- INTERFERON_ALPHA_RESPONSE-0.360
- ANDROGEN_RESPONSE-0.340
- INFLAMMATORY_RESPONSE-0.340
- INTERFERON_GAMMA_RESPONSE-0.340
- MTORC1_SIGNALING-0.340
- TGF_BETA_SIGNALING-0.340
- TNFA_SIGNALING_VIA_NFKB-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R176 | — | — | 0.878 |
| 2 | MDT-AP-1357 | Med | Medulloblastoma | 0.873 |
| 3 | MDT-AP-0578 | Med | Medulloblastoma | 0.868 |
| 4 | SRR663681 | GTEX | — | 0.862 |
| 5 | MDT-AP-1120 | Med | Medulloblastoma | 0.857 |
| 6 | SRR1318407 | GTEX | — | 0.853 |
| 7 | MDT-AP-1134 | Med | Medulloblastoma | 0.849 |
| 8 | ERR2208948 | — | — | 0.848 |
| 9 | MDT-AP-1345 | Med | Medulloblastoma | 0.844 |
| 10 | SRR1415215 | GTEX | — | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |